Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
September 10, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
September 09, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
August 05, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET
|
Icosavax, Inc.
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...